|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12...678910111213141516...9899» |
- ||||||| Trial completion, Enrollment change: ViaDUCT: Can Vitamin D Supplementation Improve Hepatitis C Cure Rates (clinicaltrials.gov) - Oct 26, 2016
P3, N=72, Completed, Sponsor: University of Dundee
Recruiting --> Completed | N=160 --> 72
- ||||||| ombitasvir (ABT-267) / AbbVie, Exviera (dasabuvir) / AbbVie
Trial completion: A Follow up Study Designed to Obtain Long Term Data on Participants Who Either Achieved a Sustained Virologic Response or Did Not Achieve a Sustained Virologic Response in an AbbVie Sponsored Hepatitis C Study (clinicaltrials.gov) - Oct 26, 2016
P3, N=479, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed | N=160 --> 72 Active, not recruiting --> Completed
- chloroquine phosphate / Generic mfg.
Trial completion: CHLOROQUINE FOR MAINTENANCE REMISSION OF AUTOIMMUNE HEPATITIS (clinicaltrials.gov) - Oct 26, 2016
P4, N=61, Completed, Sponsor: University of Sao Paulo General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, Enrollment change: Treatment of Non-alcoholic Steatohepatitis (NASH) Patients With Vitamin D (clinicaltrials.gov) - Oct 25, 2016
P2, N=22, Completed, Sponsor: University of Zurich
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=60 --> 22
- Trial completion, Enrollment change, Trial primary completion date, HEOR: GHEPA: Study of Psychological Defense Mechanisms Used by Liver Transplant Patients (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=81, Completed, Sponsor: University Hospital, Lille
Active, not recruiting --> Completed | N=60 --> 22 Recruiting --> Completed | N=120 --> 81 | Trial primary completion date: Dec 2018 --> Oct 2016
- |||| Trial primary completion date: Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents (clinicaltrials.gov) - Oct 25, 2016
P2/3, N=60, Recruiting, Sponsor: University of Manitoba
Recruiting --> Completed | N=120 --> 81 | Trial primary completion date: Dec 2018 --> Oct 2016 Trial primary completion date: Sep 2016 --> Dec 2016
- |||| Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial primary completion date: Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV . (clinicaltrials.gov) - Oct 25, 2016
P3, N=150, Recruiting, Sponsor: Universidad de Valparaiso
Trial primary completion date: Sep 2016 --> Dec 2016 Trial primary completion date: May 2016 --> Jun 2017
- ribavirin / Generic mfg.
Enrollment closed: DARE-C II: DAA-based Therapy for Recently Acquired Hepatitis C II (DAA = Directly Acting Antiviral) (clinicaltrials.gov) - Oct 21, 2016
P4, N=20, Active, not recruiting, Sponsor: Kirby Institute
Trial primary completion date: May 2016 --> Jun 2017 Recruiting --> Active, not recruiting
- Januvia (sitagliptin) / Merck (MSD)
Trial completion: Sitagliptin Versus Placebo in the Treatment of Non-alcoholic Fatty Liver Disease (clinicaltrials.gov) - Oct 20, 2016
P2, N=50, Completed, Sponsor: University of California, San Diego
Recruiting --> Active, not recruiting Not yet recruiting --> Completed
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial primary completion date: Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine (clinicaltrials.gov) - Oct 19, 2016
P3, N=793, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Completed Trial primary completion date: Oct 2008 --> May 2008
- | furaprevir (TG-2349) / TaiGen
Enrollment closed, Enrollment change, Combination therapy: Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection (clinicaltrials.gov) - Oct 19, 2016
P2, N=25, Active, not recruiting, Sponsor: TaiGen Biotechnology Co., Ltd.
Trial primary completion date: Oct 2008 --> May 2008 Recruiting --> Active, not recruiting | N=48 --> 25
- ||| Trial completion: Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=523, Completed, Sponsor: Yonsei University
Recruiting --> Active, not recruiting | N=48 --> 25 Recruiting --> Completed
- || Prolastin-C (human alpha1-proteinase inhibitor IV) / Grifols, OrphanPacific
Trial primary completion date: Study of Human Plasma-Derived Alpha1-Proteinase Inhibitor in Subjects With New-Onset Type 1 Diabetes Mellitus (clinicaltrials.gov) - Oct 17, 2016
P2, N=76, Active, not recruiting, Sponsor: Grifols Therapeutics Inc.
Recruiting --> Completed Trial primary completion date: May 2016 --> Dec 2016
- cisplatin / Generic mfg., gemcitabine / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Combination therapy, Metastases: Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC (clinicaltrials.gov) - Oct 14, 2016
P2, N=6, Terminated, Sponsor: Allina Health System
Trial primary completion date: May 2016 --> Dec 2016 N=45 --> 6 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2016; lack of funding
- | Olysio (simeprevir) / J&J, Medivir
Phase classification, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 14, 2016
P2a, N=63, Completed, Sponsor: Janssen-Cilag International NV
N=45 --> 6 | Recruiting --> Terminated | Trial primary completion date: Jan 2017 --> Sep 2016; lack of funding Phase classification: P2 --> P2a
- | oxaliplatin / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion, Metastases: Combination Treatment for Advanced Liver Cancer (clinicaltrials.gov) - Oct 13, 2016
P3, N=98, Completed, Sponsor: Shanghai Zhongshan Hospital
Phase classification: P2 --> P2a Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche, Vectibix (panitumumab) / Amgen, Takeda
Trial primary completion date: BOS2: Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases (clinicaltrials.gov) - Oct 12, 2016
P2, N=44, Terminated, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Sep 2016
- |||| ribavirin / Generic mfg., sofosbuvir/velpatasvir / Generic mfg.
Trial completion, Enrollment change: Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study (clinicaltrials.gov) - Oct 11, 2016
P2, N=69, Completed, Sponsor: Gilead Sciences
Trial primary completion date: Dec 2015 --> Sep 2016 Active, not recruiting --> Completed | N=150 --> 69
- Trial primary completion date: Validation of BIVA for Nutritional Assessment in Cirrhotic Patients (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=250, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Active, not recruiting --> Completed | N=150 --> 69 Trial primary completion date: Jul 2015 --> Jul 2016
- Trial primary completion date: Exercise Versus Diet in the Treatment of Nonalcoholic Fatty Liver Disease (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=17, Completed, Sponsor: University of Missouri-Columbia
Trial primary completion date: Jul 2015 --> Jul 2016 Trial primary completion date: Oct 2013 --> Sep 2012
- Enrollment change, Trial withdrawal, Trial primary completion date: Study of Peripheral Tissue Oxygenation in End-stage Liver Disease Patients During Liver Transplantation (clinicaltrials.gov) - Oct 4, 2016
P=N/A, N=0, Withdrawn, Sponsor: Lawson Health Research Institute
Trial primary completion date: Oct 2013 --> Sep 2012 N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2013 --> Mar 2016
- |||| Engerix-B (hepatitis B vaccine recombinant) / GSK
Trial completion, Combination therapy: Development of Read-outs in Healthy, Hepatitis B Virus Naive Adults Vaccinated With the Hepatitis B Surface Antigen (HBsAg) in Combination With a GlaxoSmithKline (GSK) Biologicals' Adjuvant System (clinicaltrials.gov) - Sep 30, 2016
P2, N=63, Completed, Sponsor: GlaxoSmithKline
N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2013 --> Mar 2016 Active, not recruiting --> Completed
- Biomarker, Trial primary completion date: HASIPRO: Unknown Cause of Acute Liver Failure (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=100, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Active, not recruiting --> Completed Trial primary completion date: Sep 2016 --> Dec 2016
- | cilofexor (GS-9674) / Gilead
Trial completion: Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients (clinicaltrials.gov) - Sep 29, 2016
P2, N=12, Completed, Sponsor: Phenex Pharmaceuticals AG
Trial primary completion date: Sep 2016 --> Dec 2016 Terminated --> Completed
- Trial completion, Enrollment change, Trial primary completion date, Biopsy: Non Invasive Assessment of Liver Fibrosis in Children: Comparison of ShearWave Elastography, Fibrotest and Liver Biopsy (clinicaltrials.gov) - Sep 29, 2016
P=N/A, N=220, Completed, Sponsor: Assistance Publique - H
Terminated --> Completed Recruiting --> Completed | N=80 --> 220 | Trial primary completion date: Sep 2016 --> May 2016
- Tracleer (bosentan) / J&J, Roche
Enrollment change, Trial termination, Trial primary completion date: Bosentan for Treatment of Hepatopulmonary Syndrome in Patients With Liver Cirrhosis (clinicaltrials.gov) - Sep 28, 2016
P2, N=6, Terminated, Sponsor: Medical University of Vienna
Recruiting --> Completed | N=80 --> 220 | Trial primary completion date: Sep 2016 --> May 2016 N=18 --> 6 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Apr 2014; too slow patient recruitment
- Odomzo (sonidegib) / Sun Pharma
Trial primary completion date, Metastases: LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis (clinicaltrials.gov) - Sep 28, 2016
P1, N=24, Recruiting, Sponsor: Jason K. Sicklick, M.D.
N=18 --> 6 | Recruiting --> Terminated | Trial primary completion date: Oct 2013 --> Apr 2014; too slow patient recruitment Trial primary completion date: Jul 2016 --> Jul 2017
- Recombivax HB (hepatitis B vaccine recombinant) / Merck (MSD)
Trial primary completion date: Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=8, Active, not recruiting, Sponsor: Rockefeller University
Trial primary completion date: Jul 2016 --> Jul 2017 Trial primary completion date: Jun 2016 --> Apr 2017
- MRX34 / Synlogic
Enrollment change, Trial termination: A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection (clinicaltrials.gov) - Sep 27, 2016
P1, N=155, Terminated, Sponsor: Mirna Therapeutics, Inc.
Trial primary completion date: Jun 2016 --> Apr 2017 N=200 --> 155 | Recruiting --> Terminated; Five immune related serious adverse events
- Tyzeka (telbivudine) / Novartis
Enrollment change, Trial withdrawal, Trial primary completion date: Efficacy of Telbivudine in Blacks/African Americans and Hispanics/Latinos With Compensated Chronic Hepatitis B During 52 Weeks (clinicaltrials.gov) - Sep 23, 2016
P4, N=0, Withdrawn, Sponsor: Novartis Pharmaceuticals
N=200 --> 155 | Recruiting --> Terminated; Five immune related serious adverse events N=90 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2011 --> Apr 2011
- Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Motivational Counseling in Preventing Smoking Relapse After Pregnancy in Pregnant Women Who Quit Smoking During Pregnancy (clinicaltrials.gov) - Sep 23, 2016
P=N/A, N=469, Completed, Sponsor: M.D. Anderson Cancer Center
N=90 --> 0 | Terminated --> Withdrawn | Trial primary completion date: Dec 2011 --> Apr 2011 Active, not recruiting --> Completed | N=650 --> 469 | Initiation date: Jul 2005 --> Apr 2002 | Trial primary completion date: Nov 2017 --> Aug 2016
- | HBVaxPro (hepatitis-B vaccine (rDNA)) / Merck (MSD), Sanofi
Trial completion: Proof Of Concept : Immunogenicity and Safety of hepB Injection in the Dermis Using VAX-ID (clinicaltrials.gov) - Sep 21, 2016
P1, N=48, Completed, Sponsor: Novosanis NV
Active, not recruiting --> Completed | N=650 --> 469 | Initiation date: Jul 2005 --> Apr 2002 | Trial primary completion date: Nov 2017 --> Aug 2016 Recruiting --> Completed
- | Enrollment open, Trial primary completion date: Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 20, 2016
P3, N=844, Recruiting, Sponsor: Sun Yat-sen University
Recruiting --> Completed Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Feb 2017
- Recentin (cediranib) / AstraZeneca
Trial completion, Enrollment change, Metastases: Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (clinicaltrials.gov) - Sep 20, 2016
P2, N=14, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2016 --> Feb 2017 Active, not recruiting --> Completed | N=36 --> 14
- Trial completion, Enrollment change: RCT of Stent Versus Standard Therapy in Oesophageal Variceal Haemorrhage (clinicaltrials.gov) - Sep 20, 2016
P=N/A, N=14, Completed, Sponsor: University College, London
Active, not recruiting --> Completed | N=36 --> 14 N=136 --> 14 | Recruiting --> Completed
- | simtuzumab (GS 6624) / Gilead
Phase classification: Simtuzumab (SIM, GS-6624) in the Treatment of Cirrhosis Due to NASH (clinicaltrials.gov) - Sep 19, 2016
P2b, N=259, Active, not recruiting, Sponsor: Gilead Sciences
N=136 --> 14 | Recruiting --> Completed Phase classification: P2 --> P2b
- Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy: AVAMET: Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer (clinicaltrials.gov) - Sep 19, 2016
P4, N=83, Active, not recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase classification: P2 --> P2b Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Dec 2017
- | Trial completion, Preclinical, Enrollment change, Trial primary completion date: Dose Finding Study to Assess Safety and Efficacy of Stem Cells in Liver Cirrhosis (clinicaltrials.gov) - Sep 16, 2016
P2, N=40, Completed, Sponsor: Stempeutics Research Pvt Ltd
Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2016 --> Dec 2017 N=60 --> 40 | Trial primary completion date: Apr 2014 --> Apr 2016 | Recruiting --> Completed
- TheraSphere (yttrium 90 microspheres) / Boston Scientific
Trial completion, Enrollment change, Trial primary completion date, Pre-transplantation: Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 15, 2016
P1, N=24, Completed, Sponsor: Northwestern University
N=60 --> 40 | Trial primary completion date: Apr 2014 --> Apr 2016 | Recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 24 | Trial primary completion date: Dec 2016 --> Jul 2015
- Pegasys (pegylated interferon ? -2a) / Roche
Trial primary completion date: An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Ribavirin Based Regimens in Patients With Chronic Hepatitis C With Previous Treatment Failure (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=282, Terminated, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=40 --> 24 | Trial primary completion date: Dec 2016 --> Jul 2015 Trial primary completion date: Jul 2016 --> Jun 2015
- decitabine / Generic mfg.
P1 data, Trial primary completion date: Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC) (clinicaltrials.gov) - Sep 15, 2016
P1/2, N=6, Recruiting, Sponsor: Universitair Ziekenhuis Brussel
Trial primary completion date: Jul 2016 --> Jun 2015 Trial primary completion date: Jun 2016 --> Dec 2016
- pentoxifylline / Generic mfg.
Trial completion: Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis (clinicaltrials.gov) - Sep 12, 2016
P=N/A, N=50, Completed, Sponsor: University of Aarhus
Trial primary completion date: Jun 2016 --> Dec 2016 Recruiting --> Completed
- Enrollment closed, Enrollment change, Trial primary completion date: Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents (clinicaltrials.gov) - Sep 12, 2016
P=N/A, N=28, Active, not recruiting, Sponsor: University of Wisconsin, Madison
Recruiting --> Completed Recruiting --> Active, not recruiting | N=120 --> 28 | Trial primary completion date: Dec 2016 --> Jul 2016
- Trial completion: Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters (clinicaltrials.gov) - Sep 9, 2016
P=N/A, N=1841, Completed, Sponsor: Peking University First Hospital
Recruiting --> Active, not recruiting | N=120 --> 28 | Trial primary completion date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed
- Trial primary completion date: Terlipressin Administration in Patients Undergoing Major Liver Resection (clinicaltrials.gov) - Sep 7, 2016
P2, N=348, Recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Trial primary completion date: Jul 2016 --> Dec 2018
- | pegylated recombinant human arginase (BCT-100) / BCT international
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, Metastases: PACOX: Pegylated Recombinant Human Arginase 1 in Combination With Oxaliplatin and Capecitabine for the Treatment of HCC (clinicaltrials.gov) - Sep 7, 2016
P2, N=17, Active, not recruiting, Sponsor: Bio-Cancer Treatment International Limited
Trial primary completion date: Jul 2016 --> Dec 2018 Recruiting --> Active, not recruiting | N=73 --> 17 | Trial primary completion date: Mar 2018 --> Sep 2016
- Signifor LAR (pasireotide long acting release) / Recordati
Trial completion, Trial primary completion date: Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Sep 7, 2016
P2, N=20, Completed, Sponsor: Lynn Feun
Recruiting --> Active, not recruiting | N=73 --> 17 | Trial primary completion date: Mar 2018 --> Sep 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016
- Enrollment closed, Enrollment change, Surgery, Metastases: Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases (clinicaltrials.gov) - Sep 6, 2016
P1, N=30, Active, not recruiting, Sponsor: UNC Lineberger Comprehensive Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Aug 2016 Suspended --> Active, not recruiting | N=40 --> 30
- | Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment closed: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (clinicaltrials.gov) - Sep 2, 2016
P2, N=36, Active, not recruiting, Sponsor: Shire
Suspended --> Active, not recruiting | N=40 --> 30 Recruiting --> Active, not recruiting
- || Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Enrollment closed, Trial primary completion date: Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C (clinicaltrials.gov) - Sep 1, 2016
P=N/A, N=3000, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Nov 2016